Some images has been designed using resources from Unsplash & Pixabay & Pexels & Freepik and some icons from Flaticon
跳到主要內容
Search
:::

余文鍾 (Wen-Chung Yu)

余文鍾(Wen-Chung Yu)圖 Return Appointment First Appointment

[Profile]

  • Education
    • National Yang-Ming University, National Yang-Ming University,
  • Career and Experience
    Current Positions：
    • - Now, Professor , Faculty of medicine, National Yang Ming Chiao Tung University, Taipei,
    • - Now, Attending physician, Department of internal medicine, Division of cardiology, Taipei Veterans General Hospital, Taipei ,
    • - Now, Resident , Internal Medicine, Taipei Veterans General Hospital,
    Experiences：
    • - , Johns Hopkins University Hosptial, USA
  • Medical Expertise
    1. General cardiology
    2. Hypertension
    3. Echocardiography
    4. Heart Failure
    5. Cardiovascular Imaging
    6. Fabry disease
    7. Cardiomyopathy
    8. Cardiac amyloidosis
  • License
    License of internal medicine, Taiwan

[Publications]

  1. Chien Y, Chou SJ, Chang YL, Leu HB, Yang YP, Tsai PH, Lai YH, Chen KH, Chang WC, Sung SH and Yu WC*. Inhibition of Arachidonate 12/15-Lipoxygenase Improves alpha-Galactosidase Efficacy in iPSC-Derived Cardiomyocytes from Fabry Patients. Int J Mol Sci. 2018;19(5):1480.
  2. Wang WT, Sung SH, Liao JN, Hsu TR, Niu DM and Yu WC*. Cardiac manifestations in patients with classical or cardiac subtype of Fabry disease. J Chin Med Assoc. 2020;83:825-829.
  3. Hung CL, Wu YW, Lin CC, Lai CH, Jyh-Ming Juang J, Chao TH, Kuo L, Sung KT, Wang CY, Wang CL, Chu CY, Yu WC* and Hou CJ. 2021 TSOC Expert Consensus on the Clinical Features, Diagnosis, and Clinical Management of Cardiac Manifestations of Fabry Disease. Acta Cardiol Sin. 2021;37:337-354.
  4. Lu DY, Huang WM, Wang WT, Hung SC, Sung SH, Chen CH, Yang YJ, Niu DM and Yu WC*. Reduced global longitudinal strain as a marker for early detection of Fabry cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2022;23:487-495.
  5. Chang HC, Kuo L, Sung SH, Weng CY, Chen CK, Niu DM, Chen SA and Yu WC*. Left Ventricular Apical Aneurysm in Fabry Disease: Implications for Clinical Significance. J Am Heart Assoc 2023; 12:e027041
  6. Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, Hung RR, Gottlieb RL, Damy T, González-Duarte A, Sarswat N, Sekijima Y, Tahara N, Taylor MS, Kubanek M, Donal E, Palecek T, Tsujita K, Tang WHW, Yu WC, Obici L, Simões M, Fernandes F, Poulsen SH, Diemberger I, Perfetto F, Solomon SD, Di Carli M, Badri P, White MT, Chen J, Yureneva E, Sweetser MT, Jay PY, Garg PP, Vest J, Gillmore JD; APOLLO-B Trial Investigators. Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis.  N Engl J Med. 2023 ;389(17):1553-1565.
  7. Fu YT, Kuo L, Yu WC* . Isolated transthyretin valvular amyloidosis. European Heart Journal; 2023 ; 44:2389.
  8. Changa,HC, Kuo L, MD; Sung SH, Niu DM, Yu WC*. Prognostic implications of left ventricular hypertrophy and mechanical function in Fabry disease: A longitudinal cohort study. J Am Soc Echocardiogr. 2024; 37(8): 787-796.
  9. Chao CJ, Jeong J, Arsanjani R, Kim K, Tsai YL, Yu WC, Farina JM, Mahmoud AK, Ayoub C, Grogan M, Kane GC, Banerjee I, Oh JK. Echocardiography-Based Deep Learning Model to Differentiate Constrictive Pericarditis and Restrictive Cardiomyopathy. JACC Cardiovasc Imaging. 2024;17(4):349-360.
  10. Yu WC. Myocardial Strain for Predicting Risk of Sudden Cardiac Death in Hypertrophic Cardiomyopathy. JACC Asia. 2024 ;4(1):23-24. 

 限於篇幅,以上謹為代表著作

回到最上